Dublin, Ireland – 21/01/2025 – Deciphex, the research pathology division of Deciphex, proudly announces the launch of Diagnexia Analytix, a comprehensive pathology service offering that integrates advanced analytics and AI-powered workflows with expert-led diagnostics to elevate study outcomes. Designed specifically for the drug development industry, Diagnexia Analytix delivers the critical pathology insights necessary for faster, more precise decision-making throughout the translational research and drug development process.

The service leverages Diagnexia’s global network of over 250 subspecialty pathologists, cutting-edge AI capabilities, and a fully digital infrastructure to deliver tailored solutions that meet the unique demands of each program.

Redefining Pathology Services for Clinical Research

Diagnexia Analytix addresses the growing complexity and demand for pathology in drug development, offering a fully integrated service designed to support every phase of a clinical trial. From complex biomarker analysis to case reporting, Diagnexia Analytix ensures reliable, actionable results within a fraction of the traditional turnaround time.

Key features of the service include:

• Customised Pathology Support: Tailored solutions for tissue biomarker evaluation, disease activity and severity scoring, and complex case reviews.
• Seamless Integration: Direct alignment with project workflows, reducing manual steps and ensuring consistent quality across activities and studies.
• Global Expertise on Demand: Access to an international network of expert pathologists for comprehensive reporting and consultation.

Improving Outcomes with Advanced Pathology Services

Diagnexia Analytix allows pharmaceutical and biotech organisations to overcome common challenges such as pathologist shortages, increased demand for complex pathology data, and delays in biomarker validation. The service is designed to empower clients with rapid, high-quality insights that improve trial efficiency and accelerate drug development timelines.

Diagnexia Analytix is more than a service—it’s a partnership," said Donal O’Shea, CEO of Diagnexia. "By combining our deep pathology expertise with state-of-the-art technology, we’re setting a new benchmark in clinical trial pathology services, offering unparalleled support to our clients at every stage of the study process​.

A Solution for Today’s Challenges

Diagnexia Analytix is uniquely positioned to meet the increasing demand for pathology services in translational research and drug development. With its focus on scalability, precision, and seamless workflow integration, the service ensures clients receive consistent, reliable results while reducing operational bottlenecks.

Aligned with Deciphex’s Vision

Diagnexia Analytix builds upon Deciphex’s commitment to transforming pathology through innovation. Leveraging one of the industry’s largest pathology data repositories, the service brings together years of experience in digital pathology and AI to deliver solutions that improve research outcomes and patient care globally​​.

About Deciphex

Deciphex is a pioneering provider of AI-driven digital pathology solutions, transforming how pathology is delivered in both clinical and non-clinical settings. With a vision to accelerate certainty in diagnostics and drug development, Deciphex combines cutting-edge technology with expert-led services to address global challenges in pathology capacity, expertise, and efficiency.

Through its clinical service, Diagnexia, Deciphex connects healthcare providers to a global network of subspecialty pathologists, offering streamlined, high-quality diagnostic reporting with industry-leading turnaround times. Meanwhile, its research platform, Patholytix, supports pharmaceutical and biotechnology companies in advancing drug development through digital pathology workflows and AI-powered analysis.

For more information about Diagnexia Analytix, visit www.diagnexia.com/analytix.

‍